A qualitative review of neoadjuvant chemotherapy in resectable pancreatic adenocarcinoma

Alex B. Blair, Rebecca Sorber, Noah S. Rozich, Richard Burkhart

Research output: Contribution to journalReview article

Abstract

The aim of this study was to evaluate outcomes of patients with resectable pancreatic adenocarcinoma (PDAC) who underwent neoadjuvant chemotherapy. The MEDLINE and PubMed databases were searched to identify relevant original articles investigating neoadjuvant therapy in resectable PDAC. Qualitative analyses were performed to investigate patient selection, disease stage, impact on perioperative outcomes, and cost-effectiveness. Forty-three studies met inclusion criteria for this review. Neoadjuvant chemotherapy for upfront resectable PDAC is cost-effective, safe, may result in lower stage disease and has potential survival advantages. With proper patient selection, neoadjuvant chemotherapy is an appropriate approach for upfront resectable PDAC. Nevertheless, the risk for disease progression and losing a curative surgical window highlights the need for appropriate patient identification, further discovery of superior biomarkers or molecular profiles representative of positive treatment response, and additional prospective comparative study.

Original languageEnglish (US)
Pages (from-to)973-984
Number of pages12
JournalPancreas
Volume48
Issue number8
DOIs
StatePublished - Sep 1 2019

Fingerprint

Adenocarcinoma
Drug Therapy
Patient Selection
Neoadjuvant Therapy
PubMed
MEDLINE
Cost-Benefit Analysis
Disease Progression
Biomarkers
Databases
Prospective Studies
Costs and Cost Analysis
Survival
Therapeutics

Keywords

  • neoadjuvant therapy
  • pancreatic neoplasms
  • preoperative chemotherapy
  • resectable pancreatic cancer
  • upfront resectable

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology

Cite this

A qualitative review of neoadjuvant chemotherapy in resectable pancreatic adenocarcinoma. / Blair, Alex B.; Sorber, Rebecca; Rozich, Noah S.; Burkhart, Richard.

In: Pancreas, Vol. 48, No. 8, 01.09.2019, p. 973-984.

Research output: Contribution to journalReview article

Blair, Alex B. ; Sorber, Rebecca ; Rozich, Noah S. ; Burkhart, Richard. / A qualitative review of neoadjuvant chemotherapy in resectable pancreatic adenocarcinoma. In: Pancreas. 2019 ; Vol. 48, No. 8. pp. 973-984.
@article{6487e3da1e154f859cc9347a06965537,
title = "A qualitative review of neoadjuvant chemotherapy in resectable pancreatic adenocarcinoma",
abstract = "The aim of this study was to evaluate outcomes of patients with resectable pancreatic adenocarcinoma (PDAC) who underwent neoadjuvant chemotherapy. The MEDLINE and PubMed databases were searched to identify relevant original articles investigating neoadjuvant therapy in resectable PDAC. Qualitative analyses were performed to investigate patient selection, disease stage, impact on perioperative outcomes, and cost-effectiveness. Forty-three studies met inclusion criteria for this review. Neoadjuvant chemotherapy for upfront resectable PDAC is cost-effective, safe, may result in lower stage disease and has potential survival advantages. With proper patient selection, neoadjuvant chemotherapy is an appropriate approach for upfront resectable PDAC. Nevertheless, the risk for disease progression and losing a curative surgical window highlights the need for appropriate patient identification, further discovery of superior biomarkers or molecular profiles representative of positive treatment response, and additional prospective comparative study.",
keywords = "neoadjuvant therapy, pancreatic neoplasms, preoperative chemotherapy, resectable pancreatic cancer, upfront resectable",
author = "Blair, {Alex B.} and Rebecca Sorber and Rozich, {Noah S.} and Richard Burkhart",
year = "2019",
month = "9",
day = "1",
doi = "10.1097/MPA.0000000000001376",
language = "English (US)",
volume = "48",
pages = "973--984",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - A qualitative review of neoadjuvant chemotherapy in resectable pancreatic adenocarcinoma

AU - Blair, Alex B.

AU - Sorber, Rebecca

AU - Rozich, Noah S.

AU - Burkhart, Richard

PY - 2019/9/1

Y1 - 2019/9/1

N2 - The aim of this study was to evaluate outcomes of patients with resectable pancreatic adenocarcinoma (PDAC) who underwent neoadjuvant chemotherapy. The MEDLINE and PubMed databases were searched to identify relevant original articles investigating neoadjuvant therapy in resectable PDAC. Qualitative analyses were performed to investigate patient selection, disease stage, impact on perioperative outcomes, and cost-effectiveness. Forty-three studies met inclusion criteria for this review. Neoadjuvant chemotherapy for upfront resectable PDAC is cost-effective, safe, may result in lower stage disease and has potential survival advantages. With proper patient selection, neoadjuvant chemotherapy is an appropriate approach for upfront resectable PDAC. Nevertheless, the risk for disease progression and losing a curative surgical window highlights the need for appropriate patient identification, further discovery of superior biomarkers or molecular profiles representative of positive treatment response, and additional prospective comparative study.

AB - The aim of this study was to evaluate outcomes of patients with resectable pancreatic adenocarcinoma (PDAC) who underwent neoadjuvant chemotherapy. The MEDLINE and PubMed databases were searched to identify relevant original articles investigating neoadjuvant therapy in resectable PDAC. Qualitative analyses were performed to investigate patient selection, disease stage, impact on perioperative outcomes, and cost-effectiveness. Forty-three studies met inclusion criteria for this review. Neoadjuvant chemotherapy for upfront resectable PDAC is cost-effective, safe, may result in lower stage disease and has potential survival advantages. With proper patient selection, neoadjuvant chemotherapy is an appropriate approach for upfront resectable PDAC. Nevertheless, the risk for disease progression and losing a curative surgical window highlights the need for appropriate patient identification, further discovery of superior biomarkers or molecular profiles representative of positive treatment response, and additional prospective comparative study.

KW - neoadjuvant therapy

KW - pancreatic neoplasms

KW - preoperative chemotherapy

KW - resectable pancreatic cancer

KW - upfront resectable

UR - http://www.scopus.com/inward/record.url?scp=85071287147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071287147&partnerID=8YFLogxK

U2 - 10.1097/MPA.0000000000001376

DO - 10.1097/MPA.0000000000001376

M3 - Review article

C2 - 31425483

AN - SCOPUS:85071287147

VL - 48

SP - 973

EP - 984

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 8

ER -